

Official Title	TRAMP: Tumor Necrosis Factor- α Blockade and AR Inhibition in Men with CRPC
NCT Number	NCT05960578
Document Type	Study Protocol and Statistical Analysis Plan
Document Date	5/20/2026

The PI or designee will also assure that all changes in the research activity and all unanticipated problems involving risks to human subjects or others will be reported promptly to the IRB, and that no changes will be made to the protocol without prior IND Sponsor (if applicable) and IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.

If the study is under an IND, copies of relevant study-related correspondence between the Investigator and the IRB may be provided to the IND Sponsor, or its designee, by the Investigator. The PI or designee must promptly notify the IRB of any SAE occurring at the site or of any safety reports received from the IND Sponsor or designee according to the requirements of the IRB of record. The Investigator or designee will be responsible for submitting periodic progress reports to the IRB at intervals appropriate to the degree of subject risk involved in the study, but not less than once per year and at the completion or termination of the study.

22.0 STOPPING THE STUDY

The Sponsor may decide to stop the study at any point, for any reason. The following reasons will lead to premature termination of the trial:

- New convincing information leading to unfavorable risk-benefit assessment of IP, including occurrence of significant toxicity associated with IP.
- Sponsor's decision that continuation of the trial is unjustifiable for medical or ethical reasons.
- Discontinuation of development of IP.

23.0 REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7-30. doi:10.3322/caac.21387
2. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *New England Journal of Medicine.* 2017;377(4):338-351. doi:10.1056/NEJMoa1702900
3. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *New England Journal of Medicine.* 2017;377(4):352-360. doi:10.1056/NEJMoa1704174
4. Scher HI, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. Cabot RC, Harris NL, Rosenberg ES, et al., eds. *New England Journal of Medicine.* 2012;367(13):1187-1197. doi:10.1056/NEJMoa1207506
5. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. *New England Journal of Medicine.* 2014;371(5):424-433. doi:10.1056/NEJMoa1405095
6. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *New England Journal of Medicine.* 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546
7. de Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. *American Journal of Pathology.* 1999;155(6):1985-1992. doi:10.1016/S0002-9440(10)65517-4
8. Putzi MJ, de Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. *Urology.* 2000;56(5):828-832. doi:10.1016/S0090-4295(00)00776-7
9. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. *Carcinogenesis.* 2009;30(7):1073-1081. doi:10.1093/carcin/bgp127
10. de Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. *Nat Rev Cancer.* 2007;7(4):256-269. doi:10.1038/nrc2090

11. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF- α correlate with clinicopathological features and patient survival in patients with prostate cancer. *Br J Cancer*. 2004;90(12):2312-2316. doi:10.1038/sj.bjc.6601814
12. Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. *Prostate*. 2014;74(8):820-828. doi:10.1002/pros.22788
13. Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. *Cancers (Basel)*. 2020;12(10):2984. doi:10.3390/cancers12102984
14. Lopez-Bujanda ZA, Haffner MC, Chaimowitz MG, et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. *Nat Cancer*. 2021;2(8):803-818. doi:10.1038/s43018-021-00227-3
15. Balkwill F. Tumour necrosis factor and cancer. *Nature Reviews Cancer* 2009 9:5. 2009;9(5):361-371. doi:10.1038/nrc2628
16. Wu Y, Zhou BP. TNF- α /NF- κ B/Snail pathway in cancer cell migration and invasion. *Br J Cancer*. 2010;102(4):639-644. doi:10.1038/sj.bjc.6605530
17. Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. *Front Immunol*. 2015;6(JUL):364. doi:10.3389/fimmu.2015.00364
18. Weber JS, Postow MA. TNF α Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly? *Clin Cancer Res*. 2020;26(9):2085-2086. doi:10.1158/1078-0432.CCR-20-0387
19. F B. TNF-alpha in promotion and progression of cancer. *Cancer Metastasis Rev*. 2006;25(3):409-416. doi:10.1007/S10555-006-9005-3
20. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF- α inhibitor, in patients with advanced cancer. *Annals of Oncology*. 2008;19(7):1340-1346. doi:10.1093/annonc/mdn054
21. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor α as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. *Journal of Clinical Oncology*. 2007;25(29):4542-4549. doi:10.1200/JCO.2007.11.2136
22. Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. The TNF Paradox in Cancer Progression and Immunotherapy. *Front Immunol*. 2019;10(JULY):1818. doi:10.3389/FIMMU.2019.01818
23. Maolake A, Izumi K, Natsagdorj A, et al. Tumor necrosis factor- α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. *Cancer Sci*. 2018;109(5):1524-1531. doi:10.1111/cas.13586
24. Hawley JE, Pan S, Figg WD, et al. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. *Prostate*. 2020;80(4):336-344. doi:10.1002/pros.23948
25. Srinivasan S, Kumar R, Koduru S, Chandramouli A, Damodaran C. Inhibiting TNF-mediated signaling: A novel therapeutic paradigm for androgen independent prostate cancer. *Apoptosis*. 2010;15(2):153-161. doi:10.1007/s10495-009-0416-9
26. Wang X, Yang L, Huang F, et al. Inflammatory cytokines IL-17 and TNF- α up-regulate PD-L1 expression in human prostate and colon cancer cells. *Immunol Lett*. 2017;184:7-14. doi:10.1016/j.imlet.2017.02.006
27. Harshman LC, Wang VX, Hamid AA, et al. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). *Prostate*. 2020;80(16):1429-1437. doi:10.1002/pros.24074
28. Alumkal JJ, Sun D, Lu E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. doi:10.1073/pnas.1922207117/-/DCSupplemental
29. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. *Cancer Res*. 2012;72(6):1494-1503. doi:10.1158/0008-5472.CAN-11-3948
30. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *New England Journal of Medicine*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

31. Smith MR, Saad F, Chowdhury S, et al. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol*. 2021;79(1):150-158. doi:10.1016/j.eururo.2020.08.011
32. Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. *Journal of Clinical Oncology*. 2021;39(20):2294-2303. doi:10.1200/JCO.20.03488
33. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. *Journal of Clinical Oncology*. 2016;34(14):1652-1659. doi:10.1200/JCO.2015.65.7270
34. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. *J Clin Oncol*. 1996;14(1):296-303. doi:10.1200/jco.1996.14.1.296
35. Thall PF, Simon R. Practical Bayesian Guidelines for Phase IIB Clinical Trials. *Biometrics*. 1994;50(2):337. doi:10.2307/2533377

24.0 APPENDICES

- Appendix A: Study Calendar
- Appendix B: ECOG Performance Status Scale
- Appendix C: Treatment Table
- Appendix D: Pill diary (Apalutamide)

APPENDIX A: Study Calendar

Procedure	Screening within 42 days	Cycle 1*	Cycle 2*	Cycle 3*	Cycle 4*	Cycle 5*	Cycle 6*	Cycle 7	Cycle 9, 12, 15, 18 etc. ± 7 days (every 3 months)	Cycle 10, 13, 16, 19 etc. ± 7 days (every 3 months)	End of Tx / discontinue Tx	LTFU
Physical Exam (vitals)	X	X	X	X	X	X	X	X		X	X	
ECOG	X	X	X	X	X	X	X	X		X	X	
PSA	X	X	X	X	X	X	X			X	X	
Testosterone (total)	X											
CBC w/diff	X	X	X	X	X	X	X			X	X	
Serum Chemistries	X	X	X	X	X	X	X			X	X	
PT/INR and PTT	X											
Quantiferon Gold / HIV / Hepatitis panel ¹	X											
Cytokines (research)	X	X	X	X	X	X	X				X	
ctDNA (research)	X				X						X	
EKG	X											
CT scans/MRI ²	X			X (C3D28 ± 7 days)			X (C6D28 ± 7 days)		X (D28 ± 7 days of cycle)		X	
NM bone scan	X			X (C3D28 ± 7 days)			X (C6D28 ± 7 days)		X (D28 ± 7 days of cycle)		X	
PSMA PET scan ³	X			X (C3D28 ± 7 days)							X**	
Metastatic tumor biopsy ⁴	X				X ⁵							
Golimumab		X	X	X	X	X	X					
AE Assessment		X	X	X	X	X	X	X		X	X	
Survival												X

¹ Hepatitis panel to include: Hepatitis C antibody (HCV Ab) reflex to HCV RNA PCR if HCV Ab positive. Hepatitis B battery (including surface antigen (HBsAg) with reflex to HBV DNA PCR, hepatitis B core antibody (HBcAb), anti hepatitis B surface antibody).

² CT scan (or MRI as indicated) chest, abdomen, and pelvis (every 12 weeks ± 7 days)

³ Optional, may not consistently be covered per SOC.

⁴ If considered safe and feasible per investigator and/or interventional radiologist’s discretion

⁵ Any time during cycle 4

* Cycle length is q4weeks or 28 days ± 4 days.

** As clinically indicated.

NOTE: Apalutamide 240mg PO daily and continuous LHRH analogues will be continued throughout study as per SOC.

APPENDIX B: ECOG Performance Status Scale

ECOG Performance Status Scale

GRADE	SCALE
0	Fully active, able to carry out all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all self-care but unable to carry out work activities. Up and about more than 50% of waking hours.
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
5	Dead

APPENDIX C: Treatment Table

Treatment Table

Table 1: Dosages and Mode of Administration of Study Therapies		
Treatment (28-Day Cycle +/- 4 days)		
Drug	Dose	Time For Administration
Golimumab*	50mg SC administration	Approximately 1 minute on Day 1.
Apalutamide	PO 240mg daily	Approximately same time every 24 hours.
* https://www.janssenlabels.com/package-insert/product-instructions-for-use/SIMPONI-ifu.pdf (For RN administration)		

APPENDIX D: Pill diary (Apalutamide)

Participant Name: _____

Study ID Number: _____

Instructions:

Your Apalutamide Dose is 240 mg daily

- Complete this pill diary every time you take your study drug.
- You will take 4 x 60 mg tablets of study drug (240 mg) once daily for each 28-day cycle.
- You should take study drug at the same time each day. You can take the study drug with or without food.
- If you checked a box in the “Was this dose vomited or missed?” column, add a comment describing why the dose was missed or not taken as prescribed, or indicate the number of minutes or hours after taking a dose that you vomited. See examples on the following page.
- Should you miss a scheduled dose for whatever reason (e.g., as a result of forgetting to take the tablets or vomiting), you should take the missed dose as soon as possible on the same day and return to the normal dosing schedule the following day. If a missed dose is not remembered on the same day, extra tablets **should not** be taken to make up for the missed dose.
- You should not drink grapefruit juice as this can affect the way the study drug works.
- If you make a mistake and need to change an entry, cross out the original entry with a single line and put your initials and date next to the correct answer.

Day	Date	Time Dose was Taken	Apalutamide # of tablets	Was the dose vomited or missed?	Comments (Reason for missed or incorrect dose)
Example	02/21/2023	—:— am ☐ pm ☐	0	☐ Vomited ☐ Missed	Dose was forgotten
		8 : 30 am ☐ pm ☒	2	☐ Vomited ☐ Missed	
1		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
2		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
3		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
4		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	

5		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
6		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
7		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
8		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
9		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
10		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	

11		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	
12		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	
13		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	
14		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	
15		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	
16		—:— am pm		☐ Vomited ☐ Missed	
		—:— am pm		☐ Vomited ☐ Missed	

17		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	
18		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	
19		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	
20		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	
21		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	
22		: am ☐ pm ☐		☐ Vomited ☐ Missed	
		: am ☐ pm ☐		☐ Vomited ☐ Missed	

23		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
24		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
25		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
26		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
27		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
28		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	
		____:____ am ☐ pm ☐		☐ Vomited ☐ Missed	

29		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
30		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	
		—:— am ☐ pm ☐		☐ Vomited ☐ Missed	